NEOS Investment Management LLC Increases Stock Position in Amgen Inc. $AMGN

NEOS Investment Management LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 48.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 229,434 shares of the medical research company’s stock after purchasing an additional 74,877 shares during the period. NEOS Investment Management LLC’s holdings in Amgen were worth $64,746,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the second quarter worth about $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen during the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the 2nd quarter worth approximately $32,000. Quaker Wealth Management LLC raised its position in shares of Amgen by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen during the 3rd quarter valued at approximately $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Piper Sandler lifted their price target on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. DZ Bank boosted their target price on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Citigroup upped their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Argus lifted their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Daiwa Securities Group upped their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Amgen Trading Up 0.8%

NASDAQ:AMGN opened at $369.19 on Tuesday. The firm has a market capitalization of $198.80 billion, a P/E ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46. The business has a 50 day simple moving average of $338.43 and a 200 day simple moving average of $314.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.